Jérôme Robert1, Alix Pantel2, Audrey Mérens3, Jean-Philippe Lavigne2, Marie-Hélène Nicolas-Chanoine4. 1. Sorbonne Universités, UPMC Univ Paris 06, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI), Eq 13, F-75013 Paris, France INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI), Eq 13, F-75013 Paris, France Bactériologie-Hygiène, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, APHP, F-75013 Paris, France jerome.robert@psl.aphp.fr. 2. INSERM U1047, UFR de Médecine, Université Montpellier 1, Nîmes, France Service de Microbiologie, CHU Carémeau, Nîmes, France. 3. Laboratoire de Biologie, Hôpital d'Instruction des Armées Bégin, Saint-Mandé, France. 4. Service de Microbiologie, Hôpital Beaujon AP-HP, Clichy, France Faculté de Médecine D. Diderot-Paris 7, Paris, France INSERM UMR 1149, Université Paris 7, Paris, France.
Abstract
OBJECTIVES: To determine proportions and incidence rates of Enterobacteriaceae producing carbapenemase among those non-susceptible (NS) to carbapenems in France. METHODS: From November 2011 to April 2012, 71 laboratories recorded non-duplicate Enterobacteriaceae clinical isolates NS to at least one carbapenem and the total number of isolates of the different species. Carbapenem MICs were determined by broth microdilution and the β-lactamase content by DNA microarray. RESULTS: During the study period, the 71 laboratories identified 133 244 Enterobacteriaceae isolates, of which 846 (0.63%) were NS to at least one carbapenem. Carbapenem-NS isolates accounted for 0.07% (61/90 148) among Escherichia coli isolates, 1.1% (111/10 436) among Klebsiella pneumoniae, 8.2% (492/5971) among Enterobacter cloacae and 4.0% (84/2104) among Enterobacter aerogenes. Among the 541 available carbapenem-NS isolates, 222 (including 63 randomly selected E. cloacae) were further analysed after confirmation of carbapenem non-susceptibility. None of the Enterobacter spp. isolates produced carbapenemase. Among the other species, 28 isolates produced carbapenemases (22 OXA-48, 4 KPC and 2 NDM), accounting for an estimated proportion of carbapenemase-producing isolates of 0.08% for all species, 0.01% for E. coli and 0.27% for K. pneumoniae. The incidence-density rate in the participating hospitals was 0.0041 per 1000 hospital-days and the incidence rate was 0.0027 per 100 admissions. CONCLUSIONS: The incidence-density rate of carbapenemase-producing isolates per 1000 hospital-days was low and 30-fold lower than that of carbapenem-NS isolates (0.125) and almost 300-fold lower than that of ESBL-producing isolates (1.104) in these French hospitals.
OBJECTIVES: To determine proportions and incidence rates of Enterobacteriaceae producing carbapenemase among those non-susceptible (NS) to carbapenems in France. METHODS: From November 2011 to April 2012, 71 laboratories recorded non-duplicate Enterobacteriaceae clinical isolates NS to at least one carbapenem and the total number of isolates of the different species. Carbapenem MICs were determined by broth microdilution and the β-lactamase content by DNA microarray. RESULTS: During the study period, the 71 laboratories identified 133 244 Enterobacteriaceae isolates, of which 846 (0.63%) were NS to at least one carbapenem. Carbapenem-NS isolates accounted for 0.07% (61/90 148) among Escherichia coli isolates, 1.1% (111/10 436) among Klebsiella pneumoniae, 8.2% (492/5971) among Enterobacter cloacae and 4.0% (84/2104) among Enterobacter aerogenes. Among the 541 available carbapenem-NS isolates, 222 (including 63 randomly selected E. cloacae) were further analysed after confirmation of carbapenem non-susceptibility. None of the Enterobacter spp. isolates produced carbapenemase. Among the other species, 28 isolates produced carbapenemases (22 OXA-48, 4 KPC and 2 NDM), accounting for an estimated proportion of carbapenemase-producing isolates of 0.08% for all species, 0.01% for E. coli and 0.27% for K. pneumoniae. The incidence-density rate in the participating hospitals was 0.0041 per 1000 hospital-days and the incidence rate was 0.0027 per 100 admissions. CONCLUSIONS: The incidence-density rate of carbapenemase-producing isolates per 1000 hospital-days was low and 30-fold lower than that of carbapenem-NS isolates (0.125) and almost 300-fold lower than that of ESBL-producing isolates (1.104) in these French hospitals.
Authors: A Pantel; H Marchandin; M-F Prère; A Boutet-Dubois; N Brieu-Roche; A Gaschet; A Davin-Regli; A Sotto; J-P Lavigne Journal: Eur J Clin Microbiol Infect Dis Date: 2014-12-23 Impact factor: 3.267
Authors: Mariana Castanheira; Sarah E Costello; Leah N Woosley; Lalitagauri M Deshpande; Todd A Davies; Ronald N Jones Journal: Antimicrob Agents Chemother Date: 2014-09-29 Impact factor: 5.191
Authors: Boudewijn L M de Jonge; James A Karlowsky; Krystyna M Kazmierczak; Douglas J Biedenbach; Daniel F Sahm; Wright W Nichols Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191
Authors: Jesús Oteo; Adriana Ortega; Rosa Bartolomé; Germán Bou; Carmen Conejo; Marta Fernández-Martínez; Juan José González-López; Laura Martínez-García; Luis Martínez-Martínez; María Merino; Elisenda Miró; Marta Mora; Ferran Navarro; Antonio Oliver; Álvaro Pascual; Jesús Rodríguez-Baño; Guillermo Ruiz-Carrascoso; Patricia Ruiz-Garbajosa; Laura Zamorano; Verónica Bautista; María Pérez-Vázquez; José Campos Journal: Antimicrob Agents Chemother Date: 2015-03-30 Impact factor: 5.191